Doctor explains why a popular statin should not be prescribed

March 17, 2015

Writing in The BMJ, Dr Sidney Wolfe, founder and senior adviser to the Health Research Group at Public Citizen, says the evidence of its health benefits has always been weak - and there is now growing evidence that the drug carries a higher risk of harmful side effects.

Last year, rosuvastatin was the most prescribed brand name drug in the US, with 22.3 million prescriptions filled and $5.8bn (£3.9bn; €5.5bn) in sales. Worldwide 2013 sales were $8.2bn, the third highest for any branded drug.

The cholesterol lowering potency of rosuvastatin exceeds all other statins, explains Wolfe. However, its later approval to prevent heart attacks in a very selected group of people, was based on the results of a study which was stopped early, prompting concern that the treatment effects may have been overestimated.

There is also growing evidence that the drug carries a higher risk of serious adverse effects compared with other statins, such as an increased risk of developing diabetes.

Other serious problems were identified before rosuvastatin's approval, prompting Public Citizen to oppose its approval in 2003, and in 2004 to ask the FDA to ban the drug. These include rhabdomyolysis, a breakdown of muscle fibres that can lead to kidney failure if not promptly treated, and increased levels of blood and protein in the urine that can progress to kidney disease.

Given the evidence of more serious risks and less clinical benefit than other statins how has the drug fared so well for so long, asks Wolfe?

He points to an October 2003 Lancet editorial that said "AstraZeneca has pushed its marketing machine too hard and too fast" and a letter from the FDA to AstraZeneca in December 2004 demanding that it immediately stop an advertisement in the Washington Post containing false and misleading information about Crestor's risks.

The advert was in response to a Washington Post article entitled "Campaign Waged against Crestor," discussing safety concerns of the FDA and Public Citizen about Crestor, explains Wolfe. The FDA also wrote to the company again the following year about "misleading superiority claims" for Crestor in other promotional materials.

When patents expired for three other popular statins (simvastatin, pravastatin, and atorvastatin), the rise in generic prescriptions quickly equaled or exceeded the sharp decreases in brand name prescriptions, says Wolfe.

The patent for rosuvastatin expires in 2016, and with it AstraZeneca's need to promote it. "But for the sake of the public's health, we must hope that the drug's disadvantages will lead to a sharp decline in its use before next year," he concludes.
-end-


BMJ

Related Statins Articles from Brightsurf:

Being in treatment with statins reduces COVID-19 mortality by 22% to 25%
A research by the Universitat Rovira i Virgili (URV) and Pere Virgili Institut (IISPV) led by LluĂ­s Masana has found that people who are being treated with statins have a 22% to 25% lower risk of dying from COVID-19.

Twitter data research reveals more about what patients think about statins
More than one in seven people taking statins -- prescribed to lower cholesterol levels -- believed that meant they could still eat unhealthy foods, a new study shows.

Statins starve cancer cells to death
More than 35 million Americans take statin drugs daily to lower their blood cholesterol levels.

Statins linked to higher diabetes risk
Individuals who take cholesterol-lowering statins may be at higher risk for developing high blood sugar levels, insulin resistance, and eventually type 2 diabetes, according to an analysis published in the British Journal of Clinical Pharmacology.

Statins could protect against motor neurone disease
High cholesterol has been found to be a possible risk factor for the development of motor neurone disease (MND), according to a large study of genetic data led in the UK by Queen Mary University of London, in collaboration with the National Institutes of Health in the USA.

Statins are more effective for those who follow the Mediterranean diet
For those who have already had a heart attack or a stroke, the combination of statins and Mediterranean Diet appears to be the most effective choice to reduce the risk of mortality, especially from cardiovascular causes.

Statins have low risk of side effects
Cholesterol-lowering statin drugs are associated with a low risk of side effects.

Statins overprescribed for primary prevention
Taking cholesterol-lowering drugs, or statins, as a preventive measure can reduce the risk of cardiovascular disease.

Many older adults do not take prescribed statins properly
In a British Journal of Clinical Pharmacology study of older adults prescribed statins, first-year nonadherence and discontinuation rates were high.

Statins show little promise for conditions other than heart disease
Medicines commonly prescribed to reduce people's risk of heart attack may have limited use for treating other diseases, research suggests.

Read More: Statins News and Statins Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.